XML 64 R49.htm IDEA: XBRL DOCUMENT
v3.25.0.1

REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | $ 28,754 | $ 27,116 | $ 27,281
U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 20,591 | 19,438 | 18,884
Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 4,634 | 4,310 | 4,469
Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,529 | 3,368 | 3,928
Product sales |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 28,610 | 26,934 | 26,982
Product sales | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 20,508 | 19,377 | 18,716
Product sales | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 4,576 | 4,197 | 4,342
Product sales | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,526 | 3,361 | 3,924
Total HIV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19,612 | 18,175 | 17,194
Total HIV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 15,918 | 14,848 | 13,820
Total HIV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,339 | 2,102 | 2,219
Total HIV | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,355 | 1,226 | 1,155
Biktarvy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 13,423 | 11,850 | 10,390
Biktarvy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 10,855 | 9,692 | 8,510
Biktarvy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,509 | 1,253 | 1,103
Biktarvy | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,060 | 905 | 777
Descovy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,113 | 1,985 | 1,872
Descovy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,902 | 1,771 | 1,631
Descovy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 100 | 100 | 118
Descovy | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 110 | 114 | 123
Genvoya |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,762 | 2,060 | 2,404
Genvoya | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,498 | 1,752 | 1,983
Genvoya | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 180 | 205 | 284
Genvoya | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 84 | 103 | 136
Odefsey |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,288 | 1,350 | 1,469
Odefsey | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 957 | 1,012 | 1,058
Odefsey | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 290 | 294 | 364
Odefsey | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 41 | 44 | 47
Symtuza - Revenue share |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 592 | 529 | 530
Symtuza - Revenue share | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 450 | 382 | 348
Symtuza - Revenue share | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 130 | 133 | 168
Symtuza - Revenue share | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 13 | 14
Other HIV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 434 | 401 | 530
Other HIV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 257 | 238 | 290
Other HIV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 129 | 116 | 182
Other HIV | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 48 | 47 | 59
Total Oncology |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,289 | 2,932 | 2,139
Total Oncology | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,798 | 1,833 | 1,494
Total Oncology | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,098 | 875 | 573
Total Oncology | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 393 | 224 | 73
Total Cell Therapy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,973 | 1,869 | 1,459
Total Cell Therapy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 896 | 1,055 | 968
Total Cell Therapy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 804 | 658 | 430
Total Cell Therapy | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 274 | 156 | 60
Tecartus |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 403 | 370 | 299
Tecartus | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 234 | 245 | 221
Tecartus | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 138 | 110 | 75
Tecartus | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 31 | 15 | 3
Yescarta |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,570 | 1,498 | 1,160
Yescarta | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 662 | 811 | 747
Yescarta | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 666 | 547 | 355
Yescarta | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 242 | 140 | 57
Trodelvy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,315 | 1,063 | 680
Trodelvy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 902 | 777 | 525
Trodelvy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 294 | 217 | 143
Trodelvy | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 119 | 68 | 12
Total Liver Disease |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,021 | 2,784 | 2,798
Total Liver Disease | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,601 | 1,421 | 1,440
Total Liver Disease | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 545 | 511 | 525
Total Liver Disease | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 876 | 852 | 833
Sofosbuvir/Velpatasvir |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,596 | 1,537 | 1,530
Sofosbuvir/Velpatasvir | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 922 | 859 | 844
Sofosbuvir/Velpatasvir | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 299 | 323 | 355
Sofosbuvir/Velpatasvir | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 374 | 355 | 331
Vemlidy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 959 | 862 | 842
Vemlidy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 486 | 410 | 429
Vemlidy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 44 | 38 | 35
Vemlidy | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 428 | 414 | 379
Other Liver Disease |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 467 | 385 | 426
Other Liver Disease | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 192 | 152 | 167
Other Liver Disease | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 202 | 150 | 135
Other Liver Disease | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 73 | 83 | 124
Veklury |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,799 | 2,184 | 3,905
Veklury | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 892 | 972 | 1,575
Veklury | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 284 | 408 | 702
Veklury | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 623 | 805 | 1,628
Total Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 889 | 859 | 946
Total Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 299 | 304 | 388
Total Other | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 310 | 301 | 323
Total Other | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 280 | 255 | 235
AmBisome |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 533 | 492 | 497
AmBisome | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 44 | 43 | 57
AmBisome | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 276 | 260 | 258
AmBisome | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 212 | 189 | 182
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 356 | 367 | 449
Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 255 | 261 | 331
Other | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 34 | 40 | 65
Other | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 68 | 66 | 53
Royalty, contract and other revenues |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 144 | 182 | 299
Royalty, contract and other revenues | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 82 | 62 | 168
Royalty, contract and other revenues | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 58 | 114 | 127
Royalty, contract and other revenues | Rest of World |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | $ 4 | $ 7 | $ 4

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_RestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsSymtuzaRevenueShareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsOtherLiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |